Harmony Biosciences Holdings, Inc. (HRMY)Â
NASDAQ$33.2+0.21 (0.64%)
Market Cap
$1.89B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
621 of 919
Rank in Industry
357 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
HRMY Insider Trading Activity
HRMY Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $285,471,613 | 18 | 100 |
Related Transactions
| Dayno Jeffrey M. | PRESIDENT, CEO | 0 | $0 | 1 | $774,245 | $-774,245 |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $1.07M | $-1.07M |
| Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 0 | $0 | 11 | $4.84M | $-4.84M |
| Marshman Fund Trust II | 10 percent owner | 0 | $0 | 2 | $139.39M | $-139.39M |
| Valor IV Pharma Holdings, LLC | 10 percent owner | 0 | $0 | 2 | $139.39M | $-139.39M |
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Insider Activity of Harmony Biosciences Holdings, Inc.
Over the last 12 months, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $285.47M worth of Harmony Biosciences Holdings, Inc. stock.
On average, over the past 5 years, insiders at Harmony Biosciences Holdings, Inc. have bought $25.07M and sold $109.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,844 shares for transaction amount of $269,049 was made by Nielsen Jack (director) on 2020‑08‑26.
List of Insider Buy and Sell Transactions, Harmony Biosciences Holdings, Inc.
| 2025-03-03 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 4,869 0.0086% | $32.67 | $159,090 | +4.70% | |
| 2025-01-27 | Sale | Kapadia Sandip | CHIEF FINANCIAL OFFICER | 1,775 0.0031% | $38.05 | $67,547 | -8.93% | |
| 2025-01-27 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 1,629 0.0029% | $38.02 | $61,941 | -8.93% | |
| 2025-01-24 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 13,125 0.0227% | $37.31 | $489,634 | -8.18% | |
| 2025-01-21 | Sale | Kapadia Sandip | CHIEF FINANCIAL OFFICER | 25,000 0.0435% | $40.18 | $1M | -11.99% | |
| 2025-01-21 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 1,123 0.0019% | $40.00 | $44,920 | -11.99% | |
| 2025-01-21 | Sale | Dayno Jeffrey M. | PRESIDENT, CEO | 19,293 0.0335% | $40.13 | $774,245 | -11.99% | |
| 2025-01-16 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 29,475 0.0506% | $37.41 | $1.1M | -5.98% | |
| 2025-01-15 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 10,507 0.0185% | $37.01 | $388,841 | -1.08% | |
| 2025-01-13 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 7,180 0.0128% | $37.04 | $265,946 | +0.22% | |
| 2024-11-05 | Sale | Valor IV Pharma Holdings, LLC | 10 percent owner | 600,000 0.9614% | $30.30 | $18.18M | +3.69% | |
| 2024-11-05 | Sale | Marshman Fund Trust II | 10 percent owner | 600,000 0.9614% | $30.30 | $18.18M | +3.69% | |
| 2024-11-01 | Sale | Valor IV Pharma Holdings, LLC | 10 percent owner | 4M 6.4248% | $30.30 | $121.21M | +4.54% | |
| 2024-11-01 | Sale | Marshman Fund Trust II | 10 percent owner | 4M 6.4248% | $30.30 | $121.21M | +4.54% | |
| 2024-10-29 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 21,496 0.0369% | $40.47 | $870,018 | -16.85% | |
| 2024-10-01 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 400 0.0007% | $40.19 | $16,077 | -11.65% | |
| 2024-09-30 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 35,846 0.0635% | $40.03 | $1.43M | -13.28% | |
| 2024-09-27 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 200 0.0004% | $40.05 | $8,009 | -11.30% | |
| 2024-03-15 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 11,979 0.0211% | $32.00 | $383,328 | +5.69% | |
| 2024-03-08 | Sale | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 194 0.0004% | $32.00 | $6,208 | +8.59% |
Total: 114
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Valor IV Pharma Holdings, LLC | 10 percent owner | 6618033 11.5406% | $218.33M | 0 | 2 | |
| Marshman Fund Trust II | 10 percent owner | 6051120 10.552% | $199.63M | 1 | 2 | <0.0001% |
| Dayno Jeffrey M. | PRESIDENT, CEO | 0 0% | $0 | 0 | 10 | |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | 0 0% | $0 | 0 | 2 | |
| Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | 0 0% | $0 | 0 | 27 | |
| Novo Holdings A/S | 10 percent owner | 4409803 7.6899% | $145.48M | 1 | 0 | <0.0001% |
| Nielsen Jack | director | 2571024 4.4834% | $84.82M | 5 | 30 | <0.0001% |
| Wicki Andreas | director | 2147943 3.7456% | $70.86M | 0 | 23 | |
| Jacobs John C | PRESIDENT, CEO | 0 0% | $0 | 0 | 10 | |
| Serafin Andrew | CHIEF STRATEGY OFFICER | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.11B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.69B | |
$11,583,737 | 45 | 49.75% | $1.86B | |
$148,770,544 | 34 | 80.63% | $1.71B | |
$150,253,463 | 26 | -52.83% | $2.1B | |
$1,801,511 | 23 | 18.58% | $2.02B | |
$92,580,864 | 14 | -1.28% | $2.17B | |
$154,554,190 | 14 | 29.60% | $1.76B | |
$75,296,816 | 12 | 37.23% | $2.07B | |
$128,232,675 | 11 | 134.40% | $1.82B | |
$137,013,690 | 11 | 26.62% | $2.03B | |
$45,445,266 | 9 | -24.96% | $1.58B | |
$32,575,266 | 8 | 37.03% | $2.14B | |
Harmony Biosciences Holdings, Inc. (HRMY) | $25,073,947 | 7 | -5.99% | $1.89B |
$142,493,653 | 3 | 4.30% | $1.68B | |
$10,000,009 | 1 | 100.92% | $1.82B | |
$7,600,000 | 1 | -4.05% | $2.12B | |
$9,900,000 | 1 | -7.19% | $2.05B |
HRMY Institutional Investors: Active Positions
| Increased Positions | 166 | +86.91% | 12M | +23.35% |
| Decreased Positions | 80 | -41.88% | 9M | -17.74% |
| New Positions | 39 | New | 2M | New |
| Sold Out Positions | 29 | Sold Out | 3M | Sold Out |
| Total Postitions | 277 | +45.03% | 53M | +5.61% |
HRMY Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $245,834.00 | 12.23% | 6.97M | +1M | +23.2% | 2024-12-31 |
| Valor Management Llc | $233,484.00 | 11.61% | 6.62M | -5M | -41.01% | 2024-12-31 |
| Fmr Llc | $188,039.00 | 9.35% | 5.33M | +101,182 | +1.94% | 2024-12-31 |
| Vanguard Group Inc | $167,002.00 | 8.31% | 4.73M | +1M | +36.37% | 2024-12-31 |
| Pacer Advisors, Inc. | $80,436.00 | 4% | 2.28M | +351,582 | +18.23% | 2024-12-31 |
| State Street Corp | $55,771.00 | 2.77% | 1.58M | +340,217 | +27.42% | 2024-12-31 |
| Deep Track Capital, Lp | $51,156.00 | 2.54% | 1.45M | +1M | New | 2024-12-31 |
| Citadel Advisors Llc | $48,271.00 | 2.4% | 1.37M | +1M | +784.58% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $42,796.00 | 2.13% | 1.21M | +160,490 | +15.25% | 2024-12-31 |
| American Century Companies Inc | $38,900.00 | 1.93% | 1.1M | +246,140 | +28.74% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.